Skip to main content
. 2021 Oct 19;10(10):2793. doi: 10.3390/cells10102793

Figure 1.

Figure 1

Different strategies of direct in vivo delivery of nucleic acid-based therapies in cystic fibrosis: modified nucleic acids combined or not to a delivery vehicle are administered in vivo in patients.